Roche, Maria

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism

Zanin-Zhorov, A., Weiss, J. M., Nyuydzefe, M. S., Chen, W., Scher, J. U., Mo, R., Depoil, D., Rao, N., Liu, B., Wei, J., et al. (2014) · Proceedings of the National Academy of Sciences

Psoriasis: Treatment and PathogenesisT-cell and B-cell Immunology

Cited by 262

Avapritinib versus placebo in indolent systemic mastocytosis

Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., et al. (2023) · NEJM Evidence

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 81

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Zauderer, M. G., Szlosarek, P., Le Moulec, S., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Jahan, T., Koczywas, M., Forster, M., et al. (2018) · Journal of Clinical Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 54

A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.

Chi, S. N., McCowage, G. B., Hoffman, L., Macy, M., Doleman, S., Blakemore, S. J., Clawson, A., Daigle, S., Tang, J., Roche, M., et al. (2016) · Journal of Clinical Oncology

Chromatin Remodeling and CancerSarcoma Diagnosis and Treatment

Cited by 8